Cadmium screening: the outpatient test is getting closer to reimbursement

Things are finally moving forward on a very real issue. Medical biologists' unions and the national health insurance system agreed on Tuesday, April 7th, on the price for cadmium exposure screening in private laboratories, paving the way for reimbursement in the coming months, subject to the usual approvals. Specifically, the measurement of cadmium in blood and urine will be billed at €27,50, an amount that establishes the framework for a test that until now has more often been performed in hospitals.

The cost-sharing arrangement is already in place: 60% for national health insurance and 40% for supplemental health insurance. François Blanchecotte, president of the SDBIO union, sums it up in a phrase that resonates with all prescribers: "We have a price, we have a funding mechanism." The biologists have also included a review clause, a way of saying that the increased availability shouldn't become excessive: if prescriptions for lead screening skyrocket beyond the observed volumes, the price can be renegotiated downwards.

A fixed price, a heavy metal on the plate

Behind these figures lies a discreet yet persistent culprit: cadmium. This heavy metal, classified as carcinogenic, mutagenic, and toxic to reproduction, is poorly eliminated by the body and accumulates silently over the years. In France, exposure is primarily through food: cereals, bread, and contamination linked in particular to the use of phosphate fertilizers, while tobacco remains a significant source for smokers. According to ANSES (the French Agency for Food, Environmental and Occupational Health & Safety), nearly half of the French population had cadmium levels exceeding health reference values ​​by 2025, with "concerning exposure at all ages, even in early childhood."

The move was expected. In June 2025, former Health Minister Yannick Neuder announced rapid access to general practitioner care for at-risk individuals already screened in hospitals, and since 2024, the French National Authority for Health (HAS) has recommended targeting individuals "potentially overexposed" based on their place of residence when soil levels exceed certain thresholds. The idea, on paper, is clear: to identify early those who live or consume food in contact with a contaminated environment, rather than discovering established exposure too late.

There remains the administrative hurdle, the kind that causes eye-rolling in doctors' offices and laboratories. The agreement still needs to be approved by the board of the National Union of Health Insurance Funds and then published in the Official Journal, a process usually completed in two to three months, according to Jean-Claude Azoulay, president of the SNMB (National Union of Medical Biologists). After that, real life will begin: doctors prescribing, patients worrying, labs absorbing the influx, and a question looming in the background, though never explicitly addressed: the actual level of exposure in a France where daily bread is more than just a metaphor.